However, Novo Nordisk (NYSE: NVO), a pioneer in the field, remains one of the leaders. That likely won't change anytime soon, since the Denmark-based pharmaceutical giant has an excellent pipeline.

Less-than-stellar phase 3 results with Novo Nordisk's highly anticipated obesity therapy CagriSema have caused its shares to fall by over a fifth, wiping around $94 billion off its market cap.

Novo Nordisk has agreed its second acquisition in the space of a month of a biotech in the obesity category, snapping up fellow Danish company Embark Biotech for €15 million (around $16 million ...

Bagsværd, Denmark, 27 January 2025 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

OpenAI on Friday launched a new AI “reasoning” model, o3-mini, the newest in the company’s o family of reasoning models. OpenAI first previewed the model in December alongside a more capable ...

But there are some families who decide to opt for a different type of four-legged friend – a pig. Stacey Robertshaw and her twins Elsie and Cole recently adopted their miniature pigs Dolly and ...